Novaliq is a pharmaceutical company that specializes in the development and commercialization of cutting-edge ocular therapeutics. Their flagship technology, EyeSol, is the first and only water-free technology in the world for ophthalmology products. Novaliq is dedicated to transforming topical therapies by leveraging their unique and versatile water-free technology.

Their goal is to unlock the full potential of eye care treatments and improve the lives of patients. Novaliq's journey began with the creation of NovaTears, the first water-free eye drop based on EyeSol, designed to treat dry eye. Since then, they have expanded their focus to include other eye care indications and topical therapeutics spaces.

With a team of seasoned industry experts, Novaliq remains committed to developing the best-in-class ocular therapies. Headquartered in Heidelberg, Germany, and with an office in Cambridge, MA, USA, Novaliq has a global presence. They collaborate with leading academic and industry partners worldwide to bring innovative therapies using their proprietary water-free technology to patients.

Notable partnerships include Bausch + Lomb, Jiangsu Hengrui Pharmaceuticals, and Betaliq Inc. Overall, Novaliq is revolutionizing the field of ocular therapeutics and paving the way for more effective and efficient treatments